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Background: Wholegrain flaxseed (FS), and its lignan component (FLC) consisting mainly of secoisolariciresinol
diglucoside (SDG), have potent lung radioprotective properties while not abrogating the efficacy of radiotherapy.
However, while the whole grain was recently shown to also have potent mitigating properties in a thoracic
radiation pneumonopathy model, the bioactive component in the grain responsible for the mitigation of lung
damage was never identified. Lungs may be exposed to radiation therapeutically for thoracic malignancies or
incidentally following detonation of a radiological dispersion device. This could potentially lead to pulmonary
inflammation, oxidative tissue injury, and fibrosis. This study aimed to evaluate the radiation mitigating effects of
FLC in a mouse model of radiation pneumonopathy.
Methods: We evaluated FLC-supplemented diets containing SDG lignan levels comparable to those in 10% and
20% whole grain diets. 10% or 20% FLC diets as compared to an isocaloric control diet (0% FLC) were given to
mice (C57/BL6) (n=15-30 mice/group) at 24, 48, or 72-hours after single-dose (13.5 Gy) thoracic x-ray treatment
(XRT). Mice were evaluated 4 months post-XRT for blood oxygenation, lung inflammation, fibrosis, cytokine and
oxidative damage levels, and survival.
Results: FLC significantly mitigated radiation-related animal death. Specifically, mice fed 0% FLC demonstrated
36.7% survival 4 months post-XRT compared to 60–73.3% survival in mice fed 10%-20% FLC initiated 24–72 hours
post-XRT. FLC also mitigated radiation-induced lung fibrosis whereby 10% FLC initiated 24-hours post-XRT
significantly decreased fibrosis as compared to mice fed control diet while the corresponding TGF-beta1 levels
detected immunohistochemically were also decreased. Additionally, 10-20% FLC initiated at any time point post
radiation exposure, mitigated radiation-induced lung injury evidenced by decreased bronchoalveolar lavage (BAL)
protein and inflammatory cytokine/chemokine release at 16 weeks post-XRT. Importantly, neutrophilic and overall
inflammatory cell infiltrate in airways and levels of nitrotyrosine and malondialdehyde (protein and lipid oxidation,
respectively) were also mitigated by the lignan diet.
Conclusions: Dietary FLC given early post-XRT mitigated radiation effects by decreasing inflammation, lung injury
and eventual fibrosis while improving survival. FLC may be a useful agent, mitigating adverse effects of radiation in
individuals exposed to incidental radiation, inhaled radioisotopes or even after the initiation of radiation therapy to
treat malignancy.
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Ionizing radiation can cause deleterious effects in living
organisms. Technological advancement has increased
human exposure to ionizing radiation through diagnostic
and therapeutic radiographic procedures, as well as
through daily workplace activities [1]. Humans are also
exposed to ionizing radiation above background levels
during air and space travel, from nuclear accidents, and
through the use of electronic devices. Additionally, glo-
bal developments over the past decade have established
terrorism as a novel and highly concerning means by
which large numbers of people could be exposed to po-
tentially lethal amounts of radiation [2].
There are at least two potential ways that a terroristic
attack could expose a population to radiation injury. If
terrorists gained possession of a nuclear warhead, det-
onation could release large amounts of radiation (in a
single “blast”) that could induce radiation sickness,
bone marrow damage, and potential lung injury. More
likely, the weapon of radiological terrorism would be a
“dirty bomb,” or a radiological dispersion device (RDD).
Conventional explosives would spread radioactive mate-
rials in the form of powder or pellets [2-4] that could
spread far away from the immediate explosion and pose
a significant health risk if inhaled. Whole-body irradi-
ation induces acute radiation syndrome (ARS) with
symptoms caused by damage to the hematopoietic,
gastrointestinal and central nervous systems [5]. The
lung becomes the target organ for radiation injury from
an RDD.
Radiation pneumonopathy is defined as a significant
clinical toxicity from thoracic radiation [6,7]. Patients
receiving large doses of radiation to the lung demon-
strate two adverse clinical scenarios [8]. An acute type
of toxic radiation response can occur within weeks after
irradiation followed by a second type of radiation-
induced lung injury which can begin within several
months after exposure; This is characterized as the “late
fibrotic” phase, in which the number of inflammatory cells
(particularly neutrophils) decrease and a marked thicken-
ing of alveolar walls due to collagen deposition can be
noted histopathologically [9,10]. Radiation pneumonopathy
has been modeled in animals [9]; C57/BL6 mice are espe-
cially susceptible to this fibrotic reaction [11-13].
Several agents, ranging from cytokines to receptor
blockers, have been tested for their efficacy in ameliorat-
ing radiation effects [12,14-16]. Most agents, even those
proven to be effective as radioprotectors (administered
prior to a radiation exposure) unfortunately are not yet
available for human use. These agents were intended as
treatments for radiation injuries resulting from the
therapeutic use of radiation — a very different scenario
compared to radiation injuries resulting from nuclear ac-
cidents or radiological terrorism. In most accidental orterrorism scenarios 1) treatment would not be initiated
until after the irradiation, thus eliminating agents that
work only when given before irradiation; 2) radiation
would be received in a short time frame and agents ef-
fective in multi-week radiation treatments might be less
effective for a single large dose of radiation; and 3) a
mitigator would need to be administered to a large
population of healthy individuals exposed to an un-
determined dose of radiation. Therefore, it has become
highly desirable to find an agent that is non-toxic,
cost-effective, and safe for multiple administrations
with beneficial effects spanning a long radiation expos-
ure and post-radiation exposure recovery phase.
Significant systemic toxicity associated with chemical
radioprotectors [17,18] has shifted the focus to plants,
herbs, as well as antioxidant agents to evaluate their
radioprotective potential [19]. Our group has identified
flaxseed (FS) and its bioactive lignan component (FLC)
as potent protectors against radiation-induced lung in-
jury when given prior to radiation exposure [20-22].
Specifically, dietary FS decreased radiation-induced oxi-
dative lung tissue damage, decreased lung inflamma-
tion and prevented lung fibrosis. Our previous work
demonstrated that FS given after thoracic radiation
mitigated radiation effects by decreasing cytokine re-
lease, inflammation, and pulmonary fibrosis while im-
proving mouse survival [22]. We also recently showed
that FS has also potent radiation mitigating properties
[22]. Our study of the whole grain, however, did not
allow for the identification of the bioactive ingredient
of FS that mediated radioprotective- and radiation-
mitigating properties. We further designed studies that
provided the first evidence that FLC, the lignan compo-
nent in FS enriched in the phenolic, secoisolariciresinol
diglucoside (SDG) surpassed whole grain FS in terms of
antioxidant, anti-inflammatory and anti-fibrotic proper-
ties [20] and was indeed responsible for the radiopro-
tective properties of the whole grain. However, the
radiation mitigating effects of FLC (and the lignan SDG
more specifically) were never investigated. The current
study was performed to ascertain whether FLC, in
addition to its radioprotective properties, could also be
an effective mitigator of radiation toxicity when ad-
ministered at different time points soon after radiation
exposure to the lung. Evidence provided in this study
provides novel, strong support that the bioactive ingre-
dient in whole grain FS responsible for its radiation
mitigating properties is the lignan component and
more specifically SDG. Focusing on SDG as a radiation
mitigator will allow detailed mechanistic studies in the
future and further development into a drug with clin-
ical usefulness thus showing how from a natural prod-
uct and a common botanical, a chemical agent can be
identified with enormous clinical implications.
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Animals
Our studies used female C57/BL6 mice, a strain well char-
acterized in the field of pulmonary radioprotection [23-25].
Mice were obtained from Charles River (Wilmington, MA)
and irradiated at 6–8 weeks of age under animal protocols
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) of the University of Pennsylvania. Animals
were housed in conventional cages under standardized
conditions with controlled temperature and humidity and
a 12:12-hour day-night light cycle. Animals had free ac-
cess to water and formulated study diets. For this study
we used n=15-30 mice for each irradiated (XRT, 13.5Gy)
group (0% FLC, 10% FLC, and 20% FLC).
Diet composition and dietary treatments
Three diets were used for this study, all based on a
semi-purified AIN-93G diet which was modified to
contain the test ingredient as previously described [20].
Importantly, control (no test ingredient added) and ex-
perimental diets were isocaloric, isonitrogenous, and
contained equal amounts of dietary lipid and carbohy-
drate. Diets contained flaxseed lignan complex (FLC) at
three different concentrations (0%, 10%, and 20%). These
concentrations reflect amounts of the main FS lignan
SDG comparable to those found in 0%, 10%, and 20%
whole grain FS diets. The FLC, enriched in the lignan
SDG (35% SDG content) was kindly provided by Archer
Daniels Midland Inc., (ADM, IL). Mice were maintained
on control (0% FLC) diet given ad libitum for three days
prior to XRT. 10% or 20% FLC diets were then started at
24, 48, and 72 hours post-XRT and continued for the
duration of the study (Scheme, Figure 1). Control-fed
mice remained on 0% FLC diet throughout the course of
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Figure 1 Experimental plan of animal feeding protocol and radiation ex
thoracic X-ray radiation therapy (13.5 Gy). Following XRT exposure, mouse coho
post-XRT. Control-fed mouse cohorts remained on 0% FLC diet throughout theAnalytical evaluation of FS lignan metabolite levels in
murine plasma samples
Circulating plasma levels (Figure 2) of the flaxseed lignans
enterodiol (ED) and enterolactone (EL) at time of sacrifice
(16 weeks post-XRT) were determined by liquid chroma-
tography tandem mass spectrometry (LC/MS/MS) as de-
scribed earlier [13,21,26] using commercially available
standards in 95% purity (Chromadex, Inc., Santa Ana, CA).
Radiation procedure
The Small Animal Radiation Research Platform (SARRP),
(Xstrahl, Camberley, United Kingdom) was used to irradi-
ate animals using a custom-made beam collimator. This
system uses a Varian model NDI-225-22 kV x-ray tube
mounted on a gantry that rotates between 0 and 120 de-
grees. The custom collimator creates a 12.5 cm circular
field with well-defined borders and with animals arranged
in a circular, “head in” arrangement (Figure 3) using a sin-
gle central shield which provides uniform irradiation to the
thoracic portion of multiple mice simultaneously. This set-
up consists of a single, anterior 225kV, 15mA x-ray beam
with a 0.15mm Cu at an SSD of 35cm that is designed to
accurately reproduce the internal radiation dose distribu-
tion in mice that were used in previous studies [21,22,27].
The dosimetry and shielding of this system has been tested
extensively [28]. The dose of radiation is a single fraction
delivered via single AP (anterior-posterior) approach. The
dose used is 13.5 Gy (roughly corresponding to LD50) as
described in our previous work [12,21,27]. For quality as-
surance, thermoluminescent dosimeters are placed over se-
lected mice, to verify correct dose administration.
Evaluation of cardiopulmonary function parameters
Prior to sacrifice, at 16 weeks post-XRT, pulse oximetry
was performed, as previously described [20], on consciousT= 16 Weeks
(sacrifice)
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Figure 2 Detection of flaxseed lignan metabolites enterodiol (ED) and enterolactone (EL) in plasma of mice fed FLC diets. Circulating
mammalian lignans, Panel A: enterodiol (ED) and Panel B: enterolactone (EL) levels in plasma of mice were determined using GC/MS/MS. Mouse
cohorts were initiated on the control 0% FLC diet 3 days prior to XRT exposure. At 24 hours post-XRT 10% FLC and 20% FLC diets were initiated.
Control-fed mouse cohorts remained on 0% FLC diet throughout the course of the study. Mouse cohorts were sacrificed at 16 weeks post-XRT and
plasma was collected. Data is represented as mean ± SEM (n=5 mice / group). No statistical significance was found between XRT and no XRT.
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signs monitor (STARR Life Sciences Corp., Oakmont, PA).
A mouse collar sensor was used to obtain measurements
for arterial oxygen saturation (SpO2), pulse distension, re-
spiratory rate, and heart rate. To minimize stress andmaintain body temperature, mice were placed on a heating
pad. Three minutes of continual readings were taken from
each mouse and sorted in a spreadsheet using a macro that
removed readings that reported any error codes. Subse-
quently, readings with no recorded error codes were
A B
C D
Figure 3 Irradiation of mouse thorax using the SARRP. Panel A: Whole thorax irradiation jig and beam arrangement. Panel B: Radial
arrangement of mice on platform. Panel C: Lead shielding of head area and upper extremities. Panel D: Lateral radiograph of mouse on the
SARRP platform using thoracic irradiation jig. Mice were irradiated using the SARRP, to deliver single fraction 13.5 Gy X-ray irradiation to the
thorax. Shielding was provided for the head only as the highly collimated field edge already limits dose to the abdomen/pelvis. The red shaded
area represents the radiation field.
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SEM for the total recording.Bronchoalveolar lavage fluid analysis
Mice were euthanized using an overdose of ketamine
(100 mg/ ml) and xylazine (20 mg/ml) at 16 weeks post
irradiation. Bronchoalveolar lavage (BAL) was then
performed as described previously [12,21,27,29]. Briefly,
BAL fluid was obtained using a 20-gauge angiocatheter
(BD Pharmingen, San Diego, CA), with the intra-tracheal
instillation of 1 ml phosphate-buffered saline (PBS)
containing an anti-protease cocktail (Sigma) and 5 mM
EDTA given in 0.5 ml increments [13,21,27]. An aliquot
was immediately separated to measure total leukocyte cell
counts (cells/ml BAL fluid) using a Coulter Cell and
Particle Counter (Beckman Coulter, Miami, FL). The
remaining lavage fluid was centrifuged at 1,200 rpm for
10 min and the cell-free supernatant was frozen at −80°C
for cytokine determination, protein analysis, and evaluation
of oxidative stress. The amount of total protein in the BAL
fluid was assayed using the BCA Protein Assay Kit (Pierce,
Rockford, IL) as per manufacturer’s instructions. Absorb-
ance was read at 560 nm (MRX Microplate Reader,
Dynatech Laboratories, Chantilly, VA) and protein levels in
mg/ml of BAL fluid were calculated.Method for Measuring TBARS in BAL
BAL cytokine concentrations were determined, as pre-
viously described [22], using Invitrogen's Mouse Cyto-
kine 20-Plex Panel (LMC0006). This multiplex panel
permits simultaneous quantification of multiple cyto-
kines in solution by capturing them onto antibody
coated spectrally distinct fluorescent microspheres and
measuring fluorescence intensity using the BioPlex 200
(Bio-Rad Laboratories, Hercules, CA) system. The
assay was performed according to the manufacturer's
protocol. All the samples were run in duplicate. The
detection limit of this kit is in pg/ml for all the in-
cluded cytokines.
Multiplexed cytokine analysis of BAL
BAL cytokine concentrations were determined, as previ-
ously described [29], using Invitrogen's Mouse Cytokine
20-Plex Panel (LMC0006). This multiplex panel permits
simultaneous quantification of multiple cytokines in solu-
tion by capturing them onto antibody coated spectrally dis-
tinct fluorescent microspheres and measuring fluorescence
intensity using the BioPlex 200 (Bio-Rad Laboratories,
Hercules, CA) system. The assay was performed
according to the manufacturer's protocol. All the sam-
ples were run in duplicate. The detection limit of this
kit is in pg/ml for all the included cytokines.
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quantitative measurement of fibrosis
The fibrosis endpoint for radiation experiments was 16
weeks post-XRT, corresponding to late radiation-induced
fibrosis as readily detectable in our model [12,21,27]
using biochemical assays and histopathological evalu-
ation. The study aimed to specifically address the mitiga-
tion properties of FLC administered post-XRT exposure
and the long-term benefits 16 weeks after initial expos-
ure. For histological studies, the lungs prior to removal
from the animal were instilled with 0.75 ml of buffered
formalin through a 20-gauge angiocatheter placed in the
trachea, immersed in buffered formalin overnight and
processed for conventional paraffin histology. Sections
were stained with hematoxylin and eosin and examined
by light microscopy. Collagen content of mouse lung was
evaluated quantitatively by determining hydroxyproline
content using acid hydrolysis [12] according to Woessner
et al. [30]. The data is expressed as μg hydroxyproline/
whole lung. Semi-quantitative evaluation of fibrosis was
done histologically by determining a radiation Fibrotic
Index (FI) as described previously [21].
Immunohistochemistry
Paraffin embedded lungs were sectioned and processed for
routine immunohistochemistry as described earlier [12].
The following antibodies were used: anti-nitrotyrosine
(rabbit polyclonal, a kind gift from Dr Harry Ischiropoulos,
University of Pennsylvania, PA) [31]; anti-TGF-beta1, clone
1D11, (Genzyme Corp.) [32].
Quantitative morphometric analysis of TGF- beta staining
Quantitative morphometric analysis of TGF- beta stain-
ing in lung tissues was performed on 5 μm serial lung
sections stained with an antibody to TGF- beta1 (clone
1D11). Image analysis was performed using the Aperio
ScanScope SC (Aperio Technologies, USA), Aperio
ImageScope. Scanned slides were analyzed using the
positive pixel count algorithm (version 8.1), by selection
of threshold values for Iwp- high (the intensity threshold
(upper limit) of weak positive pixels), Iwp-low (the inten-
sity threshold (lower limit) of weak positive pixels) and
Ip-low (the intensity threshold (lower limit) of medium
positive pixels) that distinguished TGF-beta positive from
unstained tissue. Threshold values were fixed across ana-
lysis of all sections. Data were quantified as the percent
positive tissue, i.e. the number of strongly positive pixels
(i.e. TGF-beta positive) relative to total tissue area (in
pixels). Three images from all lung lobes were evaluated
from each animal (n=3 mice per experimental cohort).
Statistical analysis
Results are expressed as mean ± SEM of two independ-
ent experiments. Statistical differences among groupswere determined using one-way analysis of variance
(ANOVA). When statistically significant differences were
found (p<0.05) individual comparisons were made using
the Bonferoni/Dunn test (Statview 4.0). The survivor
function was calculated using the Kaplan-Meier estimation
method. Subsequently, Kaplan-Meier survival curves were
generated using Stata data analysis and statistical software
(release 12, Stata Corp, College Station, TX). Overall log-
rank test for equality of survivor functions among mouse
cohorts was performed. Subsequent post-hoc analysis be-
tween individual treatments was also performed.
Results
Dietary FLC was well tolerated over prolonged ingestion
achieving biologically relevant levels
Mice tolerated FLC supplementation very well throughout
the duration of the study. Prolonged feeding (>16 weeks)
did not result in any differences in mouse weights among
non-irradiated control groups fed FLC diets (data not
shown). As a measure of diet palatability, no differences in
feed intake were also noted. 0% FLC was compared with
10% and 20% FLC diets to confirm the physiological fuel
values of treatment diets.
Circulating levels of the FS lignan metabolites
enterolactone (EL) and enterodiol (ED) were quantified
from the plasma of mice fed 0% FLC, 10% FLC and 20%
FLC diets at 16 weeks post-XRT exposure. As expected,
EL and ED were notably higher in groups fed 10% and
20% FLC compared to mice fed control, 0% FLC diet
(Figure 2). Furthermore, a separate comparison was
done to detect the difference at 16 weeks post-XRT in
plasma lignan levels in irradiated vs non-irradiated
mice fed 10% and 20% FLC diets (diets were initiated
24 hours post-XRT). ED in the mice fed FLC-fed, irra-
diated mice reached biologically relevant levels com-
parable to non-irradiated control mice fed the same
diets and sacrificed at the same time (Figure 2A). EL
was noticeably higher in irradiated mice fed 10% and
20% FLC at 24 hours post-XRT then sacrificed at 16
weeks (Figure 2B). Importantly, as anticipated, ED and
EL levels in 10% FLC cohort were comparable to those
we reported in our previous studies from feeding 10%
wholegrain flaxseed [22] while those in the 20% FLC
cohort were significantly 2-5-fold higher.
Dietary FLC improved survival after thoracic radiation
We evaluated the effect of FLC diet on mitigating XRT-
induced mortality in mice (Figure 4, A-C). The treatment
diets (10% and 20% FLC) were started at three different
time points soon after radiation exposure. As expected, the
group fed the control diet and irradiated with 13.5 Gy
showed a progressive pattern of XRT-induced mortality,
comparable to previously published reports [20,21]. How-
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Figure 4 Effect of FLC diets on the survival of mice through 16 weeks post-XRT. Kaplan-Meier curves for overall survival. Mice were pre-fed
0% FLC for 72 hours prior to single fraction thoracic X-ray radiation therapy (13.5 Gy). Following XRT exposure, mouse cohorts (n=15) were fed
10% FLC or 20% FLC diets initiated Panel A: 24, Panel B: 48 or Panel C: 72 hours post-XRT and survival was observed up to 16 weeks post-XRT.
Control-fed mouse cohorts remained on 0% FLC diet throughout the course of the study. No mice were lost in the non-irradiated cohorts (100%
survival-not shown). Log-rank p-values (shown in figure) were calculated by log-rank test between irradiated mouse cohorts. Overall survival at 16
weeks post-XRT is depicted in the bar graph.
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http://www.biomedcentral.com/1471-2407/13/179shown in Figure 4. Specifically, irradiated mice fed a 0%
FLC diet had a survival rate of 36.7% at 16-weeks as com-
pared to 60–73.3% survival in irradiated mice fed 10%-20%
FLC diets initiated 24–72 hours post-XRT. Kaplan-Meier
survival estimates were calculated for all animals involved
in the study. The survival benefit with FLC diets was statis-
tically significant with p values ranging from 0.01-0.05 as
shown in the individual comparisons (Figure 4). This
established FLC as a potent mitigator of radiation-induced



























































Figure 5 Evaluation of blood oxygenation levels and lung injury in m
to single fraction thoracic X-ray radiation therapy (13.5 Gy). Following XRT
diets initiated 24, 48, or 72 hours post-XRT. Control-fed mouse cohorts re
were sacrificed at 16 weeks post-XRT. Panel A: Pulse oximetry analysis wa
represented as mean ± SEM. *p< 0.01 for irradiated 0% FLC vs. irradiated
at 16 weeks post-XRT. Data is represented as mean ± SEM. *p< 0.01 for irDietary FLC prevented lung injury, inflammation and
improved blood oxygenation levels in mice 16 weeks
post-XRT
Blood oxygenation saturation levels 16 weeks post-
radiation exposure were measured in all mouse cohorts
to extrapolate the extent of pneumonopathy from radi-
ation exposure. Pulse oximetry was measured via a non-
invasive sensor collar clip attached to each mouse.
Figure 5A reveals the dose response of arterial oxygen
saturation (SaO2) based on percent FLC administered




+48 Hours +72 Hours
ice 16 weeks post-XRT. Mice were pre-fed 0% FLC for 72 hours prior
exposure, mouse cohorts (n=15) were fed 10% FLC or 20% FLC
mained on 0% FLC diet throughout the course of the study. Mice
s performed prior to sacrifice at 16 weeks post-XRT. Data is
10% FLC (+24 Hours). Panel B: BAL protein levels were determined
radiated 0% FLC vs. irradiated 10% and 20% FLC.
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weeks post-XRT to irradiated mice fed the same diets in-
troduced at 24, 48, or 72 hours post-XRT (Figure 5A).
Mice fed 10% FLC at 24 hours post-XRT had signifi-
cantly higher (SaO2) at 16 weeks post-XRT (p≤ 0.01)
compared with irradiated mice fed 0% FLC. Irradiated
mice fed control diet had consistently lower average oxy-
gen saturations ranging from the mid-to-high 80% range
compared to FLC fed mice who mostly maintained aver-
age saturations in the mid-to-high 90% range. Remark-
ably, irradiated mice fed 10% FLC at 24 hours post-XRT
had the highest average oxygen saturations overall. FLC
shares similar radiation mitigating properties with the
whole grain, in terms of protection of lung mechanics
post-radiation exposure [22].
Radiation induced lung injury was evaluated by quan-
tifying bronchoalveolar lavage (BAL) protein levels in all
cohorts at 16 weeks post a single dose of thoracic XRT
(Figure 5B). As anticipated, non-irradiated mice fed 0%,
10%, and 20% FLC diets showed negligible levels of BAL
proteins. Irradiated mice fed 0% FLC demonstrated
>3mg/ml BAL protein comparable to the injury shown
in our previous studies [22]. Conversely, irradiated mice
fed 10% and 20% FLC 24 post-XRT showed significantly
lower (p<0.01) BAL protein levels, and thus, lung injury
levels. Similarly, irradiated mice fed 10% FLC 48-hours
post-XRT and irradiated mice fed 20% FLC 72-hours
post-XRT had significantly lower levels of BAL protein
compared to irradiated 0% FLC fed mice.
Dietary FLC mitigated lung oxidative and nitrosative tissue
damage induced by a single fraction of thoracic radiation
Increased nitrotyrosine production is associated with
radiation-induced lung injury in rodent models [33]. We
therefore evaluated lung sections for the presence of
nitrotyrosine using immunohistochemisrty. As anticipated,
nitrotyrosine staining of histological lung sections revealed
intense positivity in sections from irradiated mice fed con-
trol diet. Staining was identified in the alveolar wall as well
as in alveolar macrophages (Figure 6A, b). Importantly,
positivity was low, almost undetectable in sections from ir-
radiated lungs, from FLC-fed mice (Figure 6A, d,f).
Additionally, lipid peroxidation indicated by MDA
levels in the BAL fluid were also significantly (p<0.01)
depressed with the FLC diet (Figure 6B). Specifically,
while radiation induced a robust 5-fold increase over
non-irradiated mice on the control diet (p<0.05), levels
remained low (comparable to non-irradiated levels) in
BAL fluid from mice fed FLC diets.
Dietary FLC mitigated lung inflammation induced by a
single fraction of thoracic radiation
Radiation pneumonopathy is in part defined as an in-
crease in inflammatory cells within the lungs. An earlyinflux of cells wreaks havoc in the parenchyma and
contributes to late collagen deposition and fibrosis. To
test if dietary FLC is as effective a mitigator of radiation
induced lung injury as whole grain FS, shown in our
previous studies [13,21,22], we measured total WBC
and neutrophils (PMN) cells/ml of bronchoalveolar lav-
age fluid (BAL) in irradiated mice fed the test diets
given at defined time points post-XRT. BAL white
blood cells per ml/ BAL fluid obtained from non-
irradiated mice fed 0% FLC, 10% FLC, and 20% FLC to-
taled approximately 50,000 cells. In contrast, irradiated
mice fed control 0% FLC diet had 125,000 cells/ml
BALF. Cell numbers were significantly reduced (p<0.01)
in irradiated mice fed 10% FLC diets 24 hours and 48
hours post-XRT exposure (Figure 7A) compared to irra-
diated mice fed control (0% FLC) diet. Notably, mice
fed 10% and 20% FLC diets 48 hours post-XRT
displayed significantly (p< 0.05) decreased inflammation
after irradiation with reduced PMN cells/ml BALF com-
pared to their irradiated counterparts fed 0% FLC diet
(Figure 7B). Importantly, irradiated mice fed 10% and
20% FLC 24 and 48 hours post-XRT showed a signifi-
cantly lower (p<0.05) influx of inflammatory cells/ml
BAL fluid compared to irradiated control mice fed 0%
FLC sacrificed at 16 weeks, reinforcing the concept
that early intervention with a radiation mitigating
agent is preferable in order to yield the greatest long-
term benefits.
Dietary FLC protected against fibrosis after a single
fraction of thoracic radiation
Semi-quantitative analyses using an established scale of
fibrosis/inflammation as previously described in Lee,
et al. 2009 [21] on Trichrome-stained sections was
performed to assess the extent of radiation fibrosis
within murine lung tissue. Representative samples of
lungs from mice fed test diets are shown in (Figure 8)
where Trichrome staining revealed higher collagen de-
position in irradiated murine lungs on 0% FLC diet
(Panels A-C) as compared to 10% (Panels D-F) and 20%
FLC diets (Panels G-I). This was supported by decreased
alveolar congestion and edema.
Results of histopathological staining for collagen were
reinforced via quantification of the hydroxyproline con-
tent in the lungs. Baseline levels of hydroxyproline
under all dietary conditions without irradiation are
shown in Figure 9A (hatched bars). Significant produc-
tion of lung hydroxyproline was induced in irradiated
mice fed control 0% FLC diet (Figure 9A, hatched).
Levels increased from baseline 89.32±6.05 μg per lung
to 149.24±6.03 μg per lung respectively in mice fed 0%
FLC. Lung tissue of irradiated mice fed 10% FLC 24 hours
post-XRT displayed significantly (p≤0.001) decreased

















































Figure 6 Oxidative and nitrosative stress in lung tissues 16 weeks post radiation exposure. Mice on control diet (0% FLC) were exposed
to a single fraction thoracic X-ray radiation therapy (13.5 Gy). Following XRT exposure, mice were switched to 10% FLC or 20% FLC diets that
were initiated 24 hours post radiation exposure while control-fed mouse cohorts remained on 0% FLC diet throughout the course of the study.
Lungs were harvested at 16 weeks post-XRT, and BAL performed followed by paraffin embedding and immunostaining for nitrotyrosine; brown
staining (Panel A). Representative lung sections are shown In Panels a-b: representing 0% FLC, Panels c-d: representing 10% FLC and Panels e-f:
representing 20% FLC. Sections were counterstained with methyl green. (Magnification 400X). Levels of thiobarbituric acid reactive substances
(TBARS) in BAL samples were determined at 16 weeks post-XRT (Panel B). Data is represented as mean ± SEM. # p< 0.05 for 0% FLC vs.
irradiated 0% FLC; *p< 0.01 for irradiated 0% FLC vs. irradiated 10% and 20% FLC.
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http://www.biomedcentral.com/1471-2407/13/179110.67±5.79 μg/lung. Significant reductions (p≤0.01) of
hydroxyproline content with feeding 20% FLC at 48 and
72 hours post-XRT compared to control-fed mice was also
noted. Lastly, significant reduction (p<0.05) in hydroxypro-
line content was also seen with 20% FLC at 24 hours post-
XRT compared to control.Along with hydroxyproline analysis, histopathological
scoring (Fibrotic Index Score Figure 9B) performed by
a lung pathologist (CCS) blinded to the study design,
demonstrated that feeding 10% FLC 48 hours post-
XRT led to significantly decreased (p<0.05) extent of






























































+48 Hours +72 Hours
* *
Figure 7 Evaluation of lung inflammation in mice at 16 weeks post-XRT. Mice were pre-fed 0% FLC for 72 hours prior to single fraction
thoracic X-ray radiation therapy (13.5 Gy). Following XRT exposure, mouse cohorts (n=15) were fed 10% FLC or 20% FLC diets initiated 24, 48, or
72 hours post-XRT. Control-fed mouse cohorts remained on 0% FLC diet throughout the course of the study. Mice were sacrificed at 16 weeks
post-XRT and bronchoalveolar lavage (BAL) fluid was collected. Panel A: Total WBC counts in BAL fluid. Data is represented as mean ± SEM. *p≤ 0.01 for
irradiated 0% FLC vs. Irradiated 10% FLC. Panel B: Total PMN cells in bronchoalveolar lavage (BAL). Data is represented as mean ± SEM. *p< 0.05 for
irradiated 0% FLC vs. irradiated 10% and 20% FLC (+48 hours).
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http://www.biomedcentral.com/1471-2407/13/179thoracic radiation. Overall, providing FLC post-XRT
showed dose response and time response curves. Al-
though not statistically significant at all points,
Figure 9B shows that the highest dose of FLC at the
earliest time point after irradiation displayed the low-
est fibrotic index score.
Flaxseed Lignan Component Modifies the Expression of
Regulatory Cytokines
Cytokine and chemokine levels in BAL fluid post-
irradiation signify activation of inflammatory pathways
that are involved in the pathogenesis of radiation-inducedlung injury. We anticipated that the lignan compo-
nent in flaxseed would mitigate activation of the in-
flammatory pathway. As seen in Table 1, 13.5 Gy
thoracic radiation significantly (p<0.01) increased key
cytokine levels in BAL fluid when compared to non-
irradiated controls. This increase in the concentration
of certain cytokines, such as FGF-basic, IL-12, and
VEGF, was significantly (p<0.05) mitigated by FLC,
irrespective of when the diet was initiated. Overall
cytokine and chemokine levels were reduced or even
undetectable in the BAL fluid of irradiated mice fed











Figure 8 Histological evaluation of lung fibrosis at 16 weeks post -XRT. Mice on control diet (0% FLC) were exposed to a single fraction
thoracic X-ray radiation therapy (13.5 Gy). Following XRT exposure, mouse cohorts (n=15) were switched to 10% FLC or 20% FLC diets that were
initiated 24, 48, or 72 hours post radiation exposure while control-fed mouse cohorts remained on 0% FLC diet throughout the course of the
study. Lungs were harvested at 16 weeks post-XRT and processed for Trichrome staining to evaluate collagen deposition and fibrosis.
Representative lung sections stained with Trichrome are shown on Panels A-C: representing 0% FLC, Panels D-F: representing 10% FLC and
Panels G-I: representing 20% FLC. (Magnification 400X).
Pietrofesa et al. BMC Cancer 2013, 13:179 Page 12 of 18
http://www.biomedcentral.com/1471-2407/13/179Positivity for TGF- beta1 in lung tissues at 16 weeks
post radiation exposure was assessed using immunohis-
tochemistry (Figure 10A) followed by image analysis to
quantify the extent of positivity (Figure 10B). Staining of
lung sections for a representative mouse cohort (diet
added 24 hours post XRT) revealed a robust 2.5-fold in-
crease in staining intensity for TGF-beta1 in irradiated
lungs fed control diets as compared to non-irradiated
controls. Importantly, TGF- beta1 positivity in lungs
from irradiated mice fed FLC diets remained at baseline
levels (p<0.03) (Figures 10B).
Discussion
We have shown here for the first time that the lig-
nan component of flaxseed, enriched in the lignan
SDG, administered within just 24–72 hours post-
thoracic radiation enhanced survival and mitigated
the chronic lung injury induced by XRT. We deter-
mined that FLC-supplemented diet mitigated the
deleterious effects of XRT by: 1) improving blood
oxygenation levels, 2) decreasing lung injury by low-
ering BAL protein levels, 3) reducing pulmonary fi-
brosis by decreasing collagen content and TGF-beta1
levels of lung tissues, 4) reducing lung inflammation
by decreasing WBC influx into the airways and most
importantly, 5) reducing oxidative tissue damage asshown by decreased protein nitration in lung tissue
and lipid peroxidation in BAL fluid 6) improving
overall animal survival.
Radiation-induced injury to adjacent normal tissue is
a notable sequelae of ionizing radiation exposure [7].
Our results indicated that XRT-induced lung inflamma-
tion and impaired blood oxygenation (decreased SaO2)
were improved with 10 and 20% FLC diet when initi-
ated after XRT. Vujaskovic and coworkers [7,34] have
shown that severe hypoxia develops months post an ini-
tial radiation exposure of lung tissues. Such hypoxia
resulted from the development of a cascade of events
leading to lung injury. Improved blood oxygenation of
all FLC-fed mouse groups may lead to decreased levels
of tissue hypoxia and may therefore explain the mitiga-
tion of adverse radiation effects even when diets are ini-
tiated post challenge. Decrease of radiation-induced
lung inflammation by a mitigator was first shown by
our group in whole grain FS [22]. This is the first re-
port that FLC mitigated pulmonary inflammation when
given hours post initial XRT challenge.
A major feature of radiation pneumonitis is a consider-
able increase in alveolar protein accumulation, an indicator
of increased vascular permeability and direct lung injury
[35]. Radiation damages resident lung cells that subse-
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No XRT
XRT (13.5 Gy)
Figure 9 Determination of fibrotic changes in murine lungs at 16 weeks post-XRT. Mice were pre-fed 0% FLC for 72 hours prior to single
fraction thoracic X-ray radiation therapy (13.5 Gy). Following XRT exposure, mouse cohorts (n=15) were fed 10% FLC or 20% FLC diets initiated 24,
48, or 72 hours post-XRT. Control-fed mouse cohorts remained on 0% FLC diet throughout the course of the study. Lungs were harvested at 16
weeks post-XRT. Panel A: Evaluation of hydroxyproline content in lungs. Data is represented as mean ± SEM. *p< 0.05 for irradiated 0% FLC vs.
irradiated 10% FLC and 20% FLC, #p≤ 0.01 for irradiated 0% FLC vs. irradiated 20% FLC (+48 and +72 hours), $p≤ 0.001 for irradiated 0% FLC vs.
irradiated 10% FLC (+24 hours). Panel B: Fibrotic Index (range=0-4) scoring. Data is represented as mean ± SEM. *p< 0.05 for irradiated 0% FLC
vs. 10% FLC (+48 hours).
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http://www.biomedcentral.com/1471-2407/13/179that recruit inflammatory cells to that area of injury while
priming the immune system in a cyclic-feedback loop
[36]. BAL protein levels are a direct and reliable measure
of lung injury, translating into actual tissue damage while
lung inflammatory cell markers (although useful) serve as
a surrogate measure of inflammation and not injury dir-
ectly [34]. Our results show significant mitigation of lung
injury in all the experimental FLC diet fed groups, regard-
less of the timing of diet initiation. This may be attributedto decreased inflammatory cell influx and membrane oxi-
dation in FLC-supplemented mice. In addition, we noted
decreased oxidative tissue damage in FLC-fed mice, as
evidenced by the tissue levels of nitrotyrosine and MDA
levels in the BAL fluid. Antioxidant agents capable of de-
creasing nitrotyrosine have also been shown by others to
be protective in radiation lung damage [37]. We first
reported [22] that whole grain FS was able to mitigate
physiological lung injury from radiation in vivo. We now
Table 1 BAL fluid cytokine levels in mice 16 weeks post-XRT
Cytokine values (pg/ml) (mean ± SEM)
FGF-basic IL-5 IL-6 IL-12 (p40/p70) KC MCP-1 VEGF
No XRT (13.5 Gy)
0% FLC ND1 4.6 ± 0.6 3.7 ± 0.2 3.2 ± 1.2 ND1 3.3 ± 0.9 10.9 ± 1.5
10 % FLC ND1 2.3 ± 0.6a 2.6 ± 0.8 0.2 ± 0.1 ND1 3.9 ± 1.0 8.5 ± 1.8
20% FLC ND1 2.1 ± 0.3a 2.4 ± 0.6a ND1 ND1 2.7 ± 0.8 5.7 ± 0.5a
XRT (+24 Hours)
0% FLC + 13.5 Gy 52.5 ± 5.5b 15.3 ± 5.3 129.0 ± 86.6 114.5 ± 24.5b 261.8 ± 52.6 77.9 ± 39.7 47.2 ± 5.0b
10% FLC + 13.5 Gy 55.3 ± 5.4 5.2 ± 0.9 ND1 73.4 ± 25.9 18.1 ± 4.4 27.2 ± 0.7 52.1 ± 9.3
20% FLC + 13.5 Gy 36.0 ± 6.4 10.7 ± 4.5 49.1 ± 22.3 91.1 ± 21.4 ND1 29.1 ± 0.9 38.4 ± 3.3
XRT (+48 Hours)
0% FLC + 13.5 Gy 52.5 ± 5.5 15.3 ± 5.3 129.0 ± 86.6 114.5 ± 24.5 261.8 ± 52.6 77.9 ± 39.7 47.2 ± 5.0
10% FLC + 13.5 Gy 61.7 ± 4.8 2.1 ± 0.3c 38.4 ± 12.8 6.7 ± 2.3c ND1 26.8 ± 1.5 7.2 ± 3.0b
20% FLC + 13.5 Gy 37.5 ± 8.6 7.3 ± 3.6 132.3 ± 75.0 83.7 ± 34.6 ND1 28.2 ± 1.7 39.7 ± 11.8
XRT (+72 Hours)
0% FLC + 13.5 Gy 52.5 ± 5.5 15.3 ± 5.3 129.0 ± 86.6 114.5 ± 24.5 261.8 ± 52.6 77.9 ± 39.7 47.2 ± 5.0
10% FLC + 13.5 Gy 35.6 ± 11.2 13.7 ± 7.6 369.7 ± 241.7 88.1 ± 32.5 425.7 ± 141.9 82.5 ± 49.9 33.0 ± 10.5
20% FLC + 13.5 Gy 34.8 ± 8.8 2.3 ± 0.8c ND1 22.7 ± 11.8c ND1 23.1 ± 0.7 30.2 ± 9.5
1ND = Not Detectable in Assay.
a = p≤0.05 for non-irradiated 0% FLC vs. non-irradiated 10% FLC and 20% FLC.
b = p<0.01 for non-irradiated 0% FLC vs. irradiated 0% FLC.
c = p<0.05 for irradiated 0% FLC vs. irradiated 10% FLC and 20% FLC.
Mice were pre-fed 0% FLC for 72 hours prior to single fraction thoracic X-ray radiation therapy (13.5 Gy). Following XRT exposure, mouse cohorts (n=15) were fed
10% FLC or 20% FLC diets initiated 24, 48, or 72 hours post-XRT. Control-fed mouse cohorts remained on 0% FLC diet throughout the course of the study. Mice
were sacrificed at 16 weeks post-XRT and bronchoalveolar lavage (BAL) fluid was collected. BAL cytokine analysis was performed and data is represented as mean
± SEM. a= p≤0.05 for non-irradiated 0% FLC vs. non-irradiated 10% FLC and 20% FLC, b= p<0.01 for non-irradiated 0% FLC vs. irradiated 0% FLC, and c= p<0.05
for irradiated 0% FLC vs. irradiated 10% FLC and 20% FLC.
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http://www.biomedcentral.com/1471-2407/13/179are the first, to our knowledge, to report that FLC demon-
strates similar in vivo beneficial properties as the whole
grain, strongly suggesting that FLC contains the key bio-
active radiation mitigator found in FS.
Radiation pneumonitis chronically evolves into fi-
brotic changes within lung tissues as a late phase of the
radiation exposure response mechanism [38]. We have
shown that whole grain FS was protective against ex-
perimental radiation fibrosis [21] and as a mitigator of
late radiation induced lung changes after one dose of
thoracic XRT [22]. Our current study showed for the
first time that via FLC, fibrotic processes associated
with high TGF-beta1 levels in lung tissues can be
blunted even when the protective agent is given post-
radiation damage, i.e., as a radiation mitigator. Notable
benefits including quantitative and qualitative physio-
logic and histopathologic endpoints from the therapeutic
use of FLC diet when initiated at 24, 48, 72 hours
posts XRT demonstrate that FLC is a highly bioactive
radiation mitigator. However, FLC-mediated decline in
both lung hydroxyproline levels and fibrotic index
were more prominent when diet was started preventively,
i.e., 3 weeks prior to XRT. This suggests that further devel-
opment or modification of the bioactive component(s) ofFLC has the potential to further improve the properties of
this novel dietary radiation mitigator.
Regulatory cytokines and chemokines play a significant
role in the inflammatory response implicated in radiation
induced lung injury. The detection of pro-inflammatory cy-
tokines, such as IL-6 and IL-12, in the BAL of irradiated
mice at 4 months post-XRT signifies a chronic and
sustained inflammatory state that occurs post-irradiation.
This heightened level of inflammation may play a signifi-
cant role in the development of pulmonary fibrosis. We
have previously reported that whole grain flaxseed when
given as radiation mitigator reduces the concentration of
pro-inflammatory cytokines present in BAL fluid [22].
Based on our current findings, this reduction in BAL cyto-
kine levels may be conferred by the lignan component in
whole grain flaxseed.
Lung lavage has been advocated as a possible counter-
measure to remove radionuclides inhaled after detonation
of an RDD [39,40]. However, this seems impractical since
multiple lavages may be required for efficient removal of
radionuclide burden using an invasive procedure with in-
herent risks and a requirement of anesthesia. Alternatively,
a plethora of synthetic and natural compounds are being






















































Figure 10 Immunohistochemical detection and quantification of TGF-beta1 in lung at 16 weeks post –XRT. Mice on control diet (0% FLC)
were exposed to a single fraction thoracic X-ray radiation therapy (13.5 Gy). Following XRT exposure, mice were switched to 10% FLC or 20% FLC
diets that were initiated 24 hours post radiation exposure while control-fed mouse cohorts remained on 0% FLC diet throughout the course of
the study. Lungs were harvested at 16 weeks post-XRT, paraffin embedded and immunostained for TGF beta1; brown staining (Panel A).
Representative lung sections are shown In Panels a-b: representing 0% FLC, Panels c-d: representing 10% FLC and Panels e-f: representing 20%
FLC. Sections were counterstained with methyl green. (Magnification 400X). Quantification of TGF-beta1 positivity (Panel B) was made using the
Aperio image analysis system. #p<0.03 as compared to irradiated 0% FLC.
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http://www.biomedcentral.com/1471-2407/13/179[19]. Agents are being developed that target inflammatory
cell recruitment, free radical production, cell death, cyto-
kine and growth factor expression, and other cell functions
[5,10,41]. While Amifostine is the only FDA approved
cytoprotective radiation mitigator its use has been associ-
ated with significant systemic toxicity [19]. Furthermore,
many of the compounds that had offered cellular radiopro-
tection in vitro have not demonstrated pre-clinical in vivo
efficacy, as summarized in a recent review by Williams
et.al. [10]. Despite much progress, the search for an effect-
ive and safe radiation mitigator with clinical usefulness has
yet to be identified.
An ideal radiation mitigator should be safe, effective,
have an easy route of administration and a long shelf-life.
The bioactive flaxseed lignan complex (FLC) enriched in
the phenolic secoisolariciresinol diglucoside (SDG) has be-
come a topic of study because of its anti-inflammatory,
antioxidant and anti-fibrotic attributes most notably in
models of thoracic radiation induced acute and chronic
lung injury [20]. Importantly, prolonged FLC administra-
tion in our animal models has not led to any significant
toxicity. This is a critically important feature, since admin-
istering a radiation mitigator that possessed even mild tox-
icity in healthy individuals to a large population following
radiation exposure could lead to severe toxicity in individ-
uals with additional medical co-morbidities. Furthermore,
FLC has a long, stable shelf life and is easy to administer
orally at an affordable price. We therefore posit that FLC
may be an effective, safe and cost-effective mitigator of ra-
diation damage.
It is evident from our results that FLC diet given within
24–72 hours after thoracic radiation exposure has benefits
in terms of morbidity and mortality. Improvement of sur-
vival using antioxidants such as N-acetyl-Cysteine (NAC)
or mitochondrial-targeted small molecule radiation dam-
age mitigators have been shown in mouse models of ab-
dominal irradiation [42] or total body irradiation [43]
respectively. To our knowledge our study is the first to re-
port that FLC served this same purpose improving survival
of animals in an experimental model of thoracic radiation
damage without any significant side effects or difficulties in
oral administration, often associated with NAC given the
unpleasant smell of its oral formulation.
In summary, we have evaluated a non-toxic, widely
available dietary phenolic compound that yielded late
protective benefits after lung exposure to radiation.
We have studied the beneficial properties of whole
grain FS in the past. Here for the first time we dem-
onstrated that FLC surpassed whole grain FS in its
antioxidant, anti-inflammatory and anti-fibrotic mitiga-
tion properties when administered after thoracic XRT.
FLC altered immediate XRT-induced markers of lung
damage, creating a radioprotective milieu post-XRT, and
provided high levels of circulating antioxidants from thecontinued metabolism of its bioactive lignans. Our long-
term goal is to provide that long awaited, safe to consume,
easy to administer, inexpensive compound for large popu-
lations in either the post-therapeutic radiation scenario or
post-radiologic terrorism (dirty-bomb) event. That com-
pound is the flaxseed lignan complex.Conclusion
There is an unmet need to identify a radiation-mitigating
agent that is effective in blunting adverse radiation effects
to the lung, while being at the same time inexpensive, non-
toxic, and easy-to-deliver to the wider population that may
include people with diverse underlying medical conditions.
Our findings that the lignan component in flaxseed is a po-
tent mitigator of radiation induced lung injury in a preclin-
ical model of radiation pneumonopathy signifies the
potential for the use of FLC in clinical settings. In the past,
we have shown that whole grain flaxseed, when given at
various time points post-XRT, was able to blunt the nega-
tive effects to the lung of acute radiation exposure. Early
intervention with the lignan component of flaxseed proves
to be equipotent in mitigating radiation-induced lung in-
jury by decreasing inflammation, cytokine release, TGF-
beta1 tissue levels, oxidative tissue damage and subsequent
collagen deposition post-XRT, while improving important
parameters such as oxygenation and overall survival that
are implicated in improved clinical outcomes.
Abbreviations
BALF: Bronchoalveolar lavage fluid; ED: enterolactone; EL: enterodiol;
FI: Fibrotic Index; FS: Flaxseed; FLC: Flaxseed Lignan Complex;
H&E: Hematoxylin and eosin; IR: Irradiation; MDA: Malondialdehyde;
PMN: Polymorphonuclear leukocyte; ROS: Reactive oxygen species;
SARRP: Small animal radiation research platform; SDG: Secoisolariciresinol
diglucoside; SEM: Standard error means; WBC: White blood cells; XRT: X-ray
Treatment.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MCS: Designed the study and individual experiments, analyzed data, wrote
the manuscript and supervised project and lab personnel; JBT: Analyzed
data, assisted in writing of the manuscript, and performed final editing; ST:
Assisted with animal experiments and manuscript preparation; SH:
performed all the irradiation procedures; RP: Performed animal experiments,
biochemical assays and conducted data analysis; FD: Assisted with pulse
oximetry; EA: Conducted animal experiments and tissue analyses; CCS:
Performed pathology assessment of histological specimens; KAC: Provided
consultation on data analysis; TB and SGC assisted with the TGF- beta
evaluation in tissues. All authors read and approved the final manuscript.
Acknowledgements
The authors wish to thank Dr. Cameron Koch for helping with the irradiation
procedure and the designing of a custom collimator for the SARRP. This
work was funded in part by: NIH-R01 CA133470 (MCS), NIH-RC1AI081251
(MCS), the University of Pennsylvania Research Foundation (MCS) and by
pilot project support from 1P30 ES013508-02 awarded to MCS (its contents
are solely the responsibility of the authors and do not necessarily represent
the official views of the NIEHS, NIH).
Pietrofesa et al. BMC Cancer 2013, 13:179 Page 17 of 18
http://www.biomedcentral.com/1471-2407/13/179Author details
1Department of Medicine, Pulmonary, Allergy and Critical Care Division,
University of Pennsylvania, 3615 Civic Center Boulevard, Abramson Research
Building, Suite 1016C, Philadelphia, PA 19104, USA. 2Radiation Oncology,
University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA.
3Department of Pathology, Jefferson University Hospital, Philadelphia, PA
19104, USA.
Received: 25 October 2012 Accepted: 19 March 2013
Published: 4 April 2013References
1. Brenner DJ, Hall EJ: Computed tomography–an increasing source of
radiation exposure. N Engl J Med 2007, 357(22):2277–2284.
2. Vogel H: Rays as weapons. Eur J Radiol 2007, 63(2):167–177.
3. Chin FK: Scenario of a dirty bomb in an urban environment and acute
management of radiation poisoning and injuries. Singapore Med J 2007,
48(10):950–957.
4. Dombroski MJ, Fischbeck PS: An integrated physical dispersion and
behavioral response model for risk assessment of radiological dispersion
device (RDD) events. Risk Anal 2006, 26(2):501–514.
5. Moulder JE: Post-irradiation approaches to treatment of radiation injuries
in the context of radiological terrorism and radiation accidents: a review.
Int J Radiat Biol 2004, 80(1):3–10.
6. Machtay M: From Abeloff's Clinical Oncology. In Pulmonary complications
of anticancer treatment. 4, chapter 62nd edition. Edited by Churchill
Livingstone. Philadelphia, PA; 2003:969–981.
7. Marks LB, Yu X, Vujaskovic Z, Small W Jr, Folz R, Anscher MS: Radiation-
induced lung injury. Semin Radiat Oncol 2003, 13(3):333–345.
8. Keane T, Van Dyk J, Rider W: Idiopathic interstitial pneumonia following bone
marrow transplantation. Int J Radiat Oncol Biol Phys 1981, 7:1365–1370.
9. Williams JP, Jackson IL, Shah JR, Czarniecki CW, Maidment BW, DiCarlo AL:
Animal models and medical countermeasures development for
radiation-induced lung damage: report from an NIAID Workshop.
Radiat Res 2012, 177(5):e0025–e0039.
10. Williams JP, Johnston CJ, Finkelstein JN: Treatment for radiation-induced
pulmonary late effects: spoiled for choice or looking in the wrong
direction? Curr Drug Targets 2010, 11(11):1386–1394.
11. Franko AJ, Sharplin J: Development of fibrosis after lung irradiation in
relation to inflammation and lung function in a mouse strain prone to
fibrosis. Radiat Res 1994, 140:347–355.
12. Machtay M, Scherpereel A, Santiago J, Lee J, McDonough J, Kinniry P, Arguiri E,
Shuvaev VV, Sun J, Cengel K, et al: Systemic polyethylene glycol-modified
(PEGylated) superoxide dismutase and catalase mixture attenuates radiation
pulmonary fibrosis in the C57/bl6 mouse. Radiother Oncol 2006, 81:196–205.
13. Lee JC, Bhora F, Sun J, Cheng G, Arguiri E, Solomides CC, Chatterjee S,
Christofidou-Solomidou M: Dietary flaxseed enhances antioxidant defenses
and is protective in a mouse model of lung ischemia-reperfusion injury.
Am J Physiol Lung Cell Mol Physiol 2008, 294(2):L255–L265.
14. Travis EL, Parkins CS, Holmes SJ, Down JD, Fowler JF: WR-2721 protection
of pneumonitis and fibrosis in mouse lung after single doses of x- rays.
Int J Radiat Oncol Biol Phys 1984, 13:1355–1359.
15. Travis EL, Newman RA, Helbing SJ: WR 2721 modification of type II cell
and endothelial cell function in mouse lung after single doses of
radiation. Int J Radiat Oncol Biol Phys 1987, 13:1355–1359.
16. Epperly M, Bray J, Kraeger S, Zwacka R, Engelhardt J, Travis E, Greenberger J:
Prevention of late effects of irradiation lung damage by manganese
superoxide dismutase gene therapy. Gene Ther 1998, 5(2):196–208.
17. Chen Y, Okunieff P: Radiation and third-generation chemotherapy.
Hematol Oncol Clin North Am 2004, 18(1):55–80.
18. Reboul FL: Radiotherapy and chemotherapy in locally advanced non-small
cell lung cancer: preclinical and early clinical data. Hematol Oncol Clin North
Am 2004, 18(1):41–53.
19. Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, Mitchell JB: Radioprotectors
and mitigators of radiation-induced normal tissue injury. Oncologist 2010,
15(4):360–371.
20. Christofidou-Solomidou M, Tyagi S, Pietrofesa R, Dukes F, Arguiri E, Turowski J,
Grieshaber PA, Solomides CC, Cengel KA: Radioprotective role in lung of the
flaxseed lignan complex enriched in the phenolic secoisolariciresinol
diglucoside (SDG). Radiat Res 2012, 178(6):568–580.21. Lee JC, Krochak R, Blouin A, Kanterakis S, Chatterjee S, Arguiri E, Vachani A,
Solomides CC, Cengel KA, Christofidou-Solomidou M: Dietary flaxseed
prevents radiation-induced oxidative lung damage, inflammation and
fibrosis in a mouse model of thoracic radiation injury. Cancer Biol Ther
2009, 8(1):47–53.
22. Christofidou-Solomidou M, Tyagi S, Tan KS, Hagan S, Pietrofesa R, Dukes F,
Arguiri E, Heitjan DF, Solomides CC, Cengel KA: Dietary flaxseed
administered post thoracic radiation treatment improves survival and
mitigates radiation-induced pneumonopathy in mice. BMC Cancer 2011,
11(1):269.
23. Dileto CL, Travis EL: Fibroblast radiosensitivity in vitro and lung fibrosis
in vivo: comparison between a fibrosis-prone and fibrosis-resistant
mouse strain. Radiat Res 1996, 146(1):61–67.
24. Sharplin J, Franko AJ: A quantitative histological study of strain-
dependent differences in the effects of irradiation on mouse lung
during the intermediate and late phases. Radiat Res 1989,
119(1):15–31.
25. Sharplin J, Franko AJ: A quantitative histological study of strain-
dependent differences in the effects of irradiation on mouse lung
during the early phase. Radiat Res 1989, 119(1):1–14.
26. Kinniry P, Amrani Y, Vachani A, Solomides CC, Arguiri E, Workman A, Carter J,
Christofidou-Solomidou M: Dietary flaxseed supplementation ameliorates
inflammation and oxidative tissue damage in experimental models of
acute lung injury in mice. J Nutr 2006, 136(6):1545–1551.
27. Lee JC, Kinniry PA, Arguiri E, Serota M, Kanterakis S, Chatterjee S, Solomides CC,
Javvadi P, Koumenis C, Cengel KA, Christofidou-Solomidou M, et al: Dietary
curcumin increases antioxidant defenses in lung, ameliorates radiation-
induced pulmonary fibrosis, and improves survival in mice. Radiat Res 2010,
173(5):590–601.
28. Baumann BC, Benci JL, Santoiemma PP, Chandrasekaran S, Hollander AB,
Kao GD, Dorsey JF: An integrated method for reproducible and
accurate image-guided stereotactic cranial irradiation of brain tumors
using the small animal radiation research platform. Transl Oncol 2012,
5(4):230–237.
29. Machtay M, Scherpereel A, Santiago J, Lee J, McDonough J, Kinniry P,
Arguiri E, Shuvaev VV, Sun J, Cengel KA, Solomides CC, Christofidou-
Solomidou M: Systemic polyethylene glycol-modified (PEGylated)
superoxide dismutase and catalase mixture attenuates radiation
pulmonary fibrosis in the C57/bl6 mouse. Radiother Oncol 2006,
81:196–205.
30. Woessner JF Jr: The determination of hydroxyproline in tissue and
protein samples containing small proportions of this imino acid.
Arch Biochem Biophys 1961, 93:440–447.
31. Heijnen HF, van Donselaar E, Slot JW, Fries DM, Blachard-Fillion B, Hodara R,
Lightfoot R, Polydoro M, Spielberg D, Thomson L, et al: Subcellular
localization of tyrosine-nitrated proteins is dictated by reactive oxygen
species generating enzymes and by proximity to nitric oxide synthase.
Free Radic Biol Med 2006, 40(11):1903–1913.
32. Anscher MS, Thrasher B, Rabbani Z, Teicher B, Vujaskovic Z:
Antitransforming growth factor-beta antibody 1D11 ameliorates normal
tissue damage caused by high-dose radiation. Int J Radiat Oncol Biol Phys
2006, 65(3):876–881.
33. Tsuji C, Shioya S, Hirota Y, Fukuyama N, Kurita D, Tanigaki T, Ohta Y,
Nakazawa H: Increased production of nitrotyrosine in lung tissue of rats
with radiation-induced acute lung injury. Am J Physiol Lung Cell Mol
Physiol 2000, 278(4):L719–L725.
34. Gauter-Fleckenstein B, Fleckenstein K, Owzar K, Jiang C, Reboucas JS,
Batinic-Haberle I, Vujaskovic Z: Early and late administration of MnTE-2
-PyP5+ in mitigation and treatment of radiation-induced lung damage.
Free Radic Biol Med 2010, 48(8):1034–1043.
35. Park KJ, Oh YT, Kil WJ, Park W, Kang SH, Chun M: Bronchoalveolar lavage
findings of radiation induced lung damage in rats. J Radiat Res (Tokyo)
2009, 50(3):177–182.
36. Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN: A perpetual
cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J
Radiat Oncol Biol Phys 1995, 33(1):99–109.
37. Rabbani ZN, Salahuddin FK, Yarmolenko P, Batinic-Haberle I, Thrasher BA,
Gauter-Fleckenstein B, Dewhirst MW, Anscher MS, Vujaskovic Z: Low
molecular weight catalytic metalloporphyrin antioxidant AEOL 10150
protects lungs from fractionated radiation. Free Radic Res 2007,
41(11):1273–1282.
Pietrofesa et al. BMC Cancer 2013, 13:179 Page 18 of 18
http://www.biomedcentral.com/1471-2407/13/17938. Travis EL, Harley RA, Fenn JO, Klobukowski CJ, Hargrove HB: Pathologic
changes in the lung following single and multi-fraction irradiation. Int J
Radiat Oncol Biol Phys 1977, 2(5–6):475–490.
39. Morgan GW, Pharm B, Breit SN: Radiation and the lung: A reevaluation of
the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys
1995, 31:361–369.
40. Muggenburg BA, Boecker BB, Hahn FF, McClellan RO: Lung lavage therapy
to lessen the biological effects of inhaled 144Ce in dogs. Radiat Res 1990,
124(2):147–155.
41. Medhora M, Gao F, Jacobs ER, Moulder JE: Radiation damage to the lung:
mitigation by angiotensin-converting enzyme (ACE) inhibitors.
Respirology 2012, 17(1):66–71.
42. Jia D, Koonce NA, Griffin RJ, Jackson C, Corry PM: Prevention and mitigation of
acute death of mice after abdominal irradiation by the antioxidant N-acetyl
-cysteine (NAC). Radiat Res 2010, 173(5):579–589.
43. Rwigema JC, Beck B, Wang W, Doemling A, Epperly MW, Shields D, Goff JP,
Franicola D, Dixon T, Frantz MC, et al: Two Strategies for the Development
of Mitochondrion-targeted Small Molecule Radiation Damage Mitigators.
Int J Radiat Oncol Biol Phys 2011, 80:860–868.
doi:10.1186/1471-2407-13-179
Cite this article as: Pietrofesa et al.: Radiation mitigating properties of
the lignan component in flaxseed. BMC Cancer 2013 13:179.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
